Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples